ERBB2 and breast cancer: Furthermore, Food and Drug Administration (FDA) has made an agreement to use pCR as an endpoint for accelerated new drug approval in high risk early breast cancer, leading to the approval of pertuzumab in NAT of HER2+ breast cancer [10].